Literature DB >> 1512230

A recombinant form of Pseudomonas exotoxin directed at the epidermal growth factor receptor that is cytotoxic without requiring proteolytic processing.

C P Theuer1, D FitzGerald, I Pastan.   

Abstract

Pseudomonas exotoxin A is composed of three structural domains that mediate cell recognition (I), membrane translocation (II), and ADP-ribosylation (III). Within the cell, the toxin is cleaved within domain II to produce a 37-kDa carboxyl-terminal fragment, containing amino acids 280-613, which is translocated to the cytosol and causes cell death. In this study, we constructed a mutant protein (PE37), composed of amino acids 280-613 of Pseudomonas exotoxin A, which does not require proteolysis to translocate. PE37 was targeted specifically to cells with epidermal growth factor receptors by inserting transforming growth factor-alpha (TGF-alpha) after amino acid 607 near the carboxyl terminus of Pseudomonas exotoxin A. PE37/TGF-alpha was very cytotoxic to cells with epidermal growth factor receptors. It was severalfold more cytotoxic than a derivative of full-length Pseudomonas exotoxin A containing TGF-alpha in the same position, probably because the latter requires intracellular proteolytic processing to exhibit its cytotoxicity, and proteolytic processing is not 100% efficient. Deletion of 2, 4, or 7 amino acids from the amino terminus of PE37/TGF-alpha greatly diminished cytotoxic activity, indicating the need for a proper amino-terminal sequence. In addition, a mutant containing an internal deletion of amino acids 314-380 was minimally active, indicating that other regions of domain II are also required for the cytotoxic activity of Pseudomonas exotoxin A.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1512230

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.486


  9 in total

1.  Engineering toxin-resistant therapeutic stem cells to treat brain tumors.

Authors:  Daniel W Stuckey; Shawn D Hingtgen; Nihal Karakas; Benjamin E Rich; Khalid Shah
Journal:  Stem Cells       Date:  2015-02       Impact factor: 6.277

Review 2.  Proteolytic activation of bacterial toxins: role of bacterial and host cell proteases.

Authors:  V M Gordon; S H Leppla
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

3.  Identification of a receptor-binding region within domain 4 of the protective antigen component of anthrax toxin.

Authors:  M Varughese; A V Teixeira; S Liu; S H Leppla
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

Review 4.  Intracellular trafficking considerations in the development of natural ligand-drug molecular conjugates for cancer.

Authors:  Dennis J Yoon; Christina T Liu; Devin S Quinlan; Parsa M Nafisi; Daniel T Kamei
Journal:  Ann Biomed Eng       Date:  2011-02-25       Impact factor: 3.934

5.  Efficiency of immunotoxin cytotoxicity is modulated by the intracellular itinerary.

Authors:  Lori L Tortorella; Nina H Pipalia; Sushmita Mukherjee; Ira Pastan; David Fitzgerald; Frederick R Maxfield
Journal:  PLoS One       Date:  2012-10-09       Impact factor: 3.240

6.  The N-terminal region of the 37-kDa translocated fragment of Pseudomonas exotoxin A aborts translocation by promoting its own export after microsomal membrane insertion.

Authors:  C P Theuer; J Buchner; D FitzGerald; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-15       Impact factor: 12.779

7.  Selective toxicity of TGF-alpha-PE40 to EGFR-positive cell lines: selective protection of low EGFR-expressing cell lines by EGF.

Authors:  J Kirk; J Carmichael; I J Stratford; A L Harris
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

8.  A target-specific chimeric toxin composed of epidermal growth factor and Pseudomonas exotoxin A with a deletion in its toxin-binding domain.

Authors:  C W Liao; T H Hseu; J Hwang
Journal:  Appl Microbiol Biotechnol       Date:  1995-07       Impact factor: 5.560

9.  Improved antitumor activity of a recombinant anti-Lewis(y) immunotoxin not requiring proteolytic activation.

Authors:  C T Kuan; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-06       Impact factor: 12.779

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.